2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2846-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JAMY ARD und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: It is important to understand if the effect of semaglutide 2.4mg (sema) on major adverse cardiovascular events (MACE) varies by race/ethnicity given prevalent disparities. This SELECT trial post hoc analysis assessed the efficacy and safety of sema for MACE risk reduction in patients with overweight/obesity and CVD without diabetes stratified by race/ethnicity.
Methods
Participants randomized to receive sema or placebo were grouped by self-reported race/ethnicity to assess the treatment effect on MACE. Cox regression models testing for interactions (race/ethnicity x treatment effect) were performed; adverse events (AEs) leading to discontinuation were summarized descriptively.
Results
Race/ethnicity were balanced across treatment arms (Figure). Sema-treated patients exhibited similar reductions in weight from baseline (Asian, Other, White, Hispanic, not Hispanic: -9%; Black: -10%). Sema consistently reduced the risk of MACE across race/ethnicity. Asian patients receiving sema had slightly greater MACE risk reduction vs those receiving placebo. The proportions of sema-treated patients with AEs (Asian: 11%; Hispanic: 15%; Black: 16%; Other, White, not Hispanic: 17%) and serious AEs (Asian, Hispanic: 3%; White, not Hispanic, Other: 4%; Black: 5%) leading to discontinuation were similar across races/ethnicities.
Conclusion
Sema reduced the relative risk of MACE and had a consistent safety profile regardless of patient race or ethnicity. Disclosure J. Ard: Consultant; Current; Novo Nordisk, Eli Lilly and Company, Amgen Inc., Roche Pharmaceuticals, Viking Therapeutics, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Zealand Pharma A/S. Research Support; Current; Weight Watchers. Consultant; Current; Epitomee. M. Knight: Consultant; Current; Novo Nordisk, Boehringer Ingelheim International GmbH. Consultant; Ended; Currax Pharmaceuticals. A.B. Bojesen: Employee; Current; Novo Nordisk. D. Rubino: Other - Advisory panel, research support, shareholder; Current; AbbVie Inc. Other - steering committee, research support; Current; Amgen Inc. Other - advisory panel, steering committee, research support; Current; AstraZeneca. Other - advisory panel, research support; Current; Boehringer Ingelheim International GmbH. Other - advisory panel, speaker, research support,; Current; Novo Nordisk. Consultant; Current; Lilly, Shionogi & Co., Ltd. Advisory Panel; Current; Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals Inc. Consultant; Current; Pfizer Inc., Roche Pharmaceuticals, Cytoki. Other - advisory, research support; Current; Terns Pharmaceutical. Advisory Panel; Current; Neuraly Inc. Consultant; Current; Ferring Pharmaceuticals. Consultant; Ended; NodThera. S. Stensen: Employee; Current; Novo Nordisk A/S. A. Traina: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. L. Wilson: Employee; Current; Novo Nordisk. R. Kushner: Advisory Panel; Current; AbbVie Inc. Consultant; Ended; Altimmune. Advisory Panel; Current; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Consultant; Current; Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Viking Therapeutics. Advisory Panel; Current; Antag, Weight Watchers, Structure.
Zitieren
APA
ARD, J., KNIGHT, M., BOJESEN, A. B., RUBINO, D., STENSEN, S., TRAINA, A., WILSON, L., & KUSHNER, R. (2026). 2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2846-lb
Vancouver
ARD J, KNIGHT M, BOJESEN AB, RUBINO D, STENSEN S, TRAINA A, et al. 2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2846-lb
BibTeX
@article{ARD2026,
author = {ARD, JAMY and KNIGHT, MICHAEL and BOJESEN, ANDERS B. and RUBINO, DOMENICA and STENSEN, SIGNE and TRAINA, ANDREA and WILSON, LAUREN and KUSHNER, ROBERT},
title = {2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2846-lb}
}
EUVIMED